JP2005506348A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005506348A5 JP2005506348A5 JP2003535727A JP2003535727A JP2005506348A5 JP 2005506348 A5 JP2005506348 A5 JP 2005506348A5 JP 2003535727 A JP2003535727 A JP 2003535727A JP 2003535727 A JP2003535727 A JP 2003535727A JP 2005506348 A5 JP2005506348 A5 JP 2005506348A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- composition
- histone deacetylase
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 173
- 150000001875 compounds Chemical class 0.000 claims 78
- 150000003839 salts Chemical class 0.000 claims 74
- 229940121372 histone deacetylase inhibitor Drugs 0.000 claims 58
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims 58
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 39
- 102000003964 Histone deacetylase Human genes 0.000 claims 26
- 108090000353 Histone deacetylase Proteins 0.000 claims 26
- 125000004104 aryloxy group Chemical group 0.000 claims 25
- 230000002401 inhibitory effect Effects 0.000 claims 25
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims 24
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 24
- 125000003118 aryl group Chemical group 0.000 claims 23
- 125000003545 alkoxy group Chemical group 0.000 claims 18
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 15
- 125000003282 alkyl amino group Chemical group 0.000 claims 12
- 125000000217 alkyl group Chemical group 0.000 claims 12
- 125000003277 amino group Chemical group 0.000 claims 12
- 125000004663 dialkyl amino group Chemical group 0.000 claims 12
- -1 hydroxylamino group Chemical group 0.000 claims 12
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 12
- 125000004947 alkyl aryl amino group Chemical group 0.000 claims 9
- 125000001769 aryl amino group Chemical group 0.000 claims 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 9
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims 6
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 6
- 150000001408 amides Chemical group 0.000 claims 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 241000124008 Mammalia Species 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims 3
- 125000003342 alkenyl group Chemical group 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical group 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 125000001624 naphthyl group Chemical group 0.000 claims 3
- 125000003386 piperidinyl group Chemical group 0.000 claims 3
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 125000005647 linker group Chemical group 0.000 claims 2
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 claims 2
- 229920000155 polyglutamine Polymers 0.000 claims 2
- 108010040003 polyglutamine Proteins 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 0 CC(C(**)=O)NC(*)=O Chemical compound CC(C(**)=O)NC(*)=O 0.000 description 7
- YOZRCCTXOPFCAM-UHFFFAOYSA-N CC(C(Nc1ccc2ncccc2c1)=O)C(Nc1cc2cccnc2cc1)=O Chemical compound CC(C(Nc1ccc2ncccc2c1)=O)C(Nc1cc2cccnc2cc1)=O YOZRCCTXOPFCAM-UHFFFAOYSA-N 0.000 description 1
- APBBTKKLSNPFDP-UHFFFAOYSA-N CC(CCC1)c2c1cccc2 Chemical compound CC(CCC1)c2c1cccc2 APBBTKKLSNPFDP-UHFFFAOYSA-N 0.000 description 1
- VRZWCYZJGUYTKU-UHFFFAOYSA-N C[n]1c2ncncc2nc1 Chemical compound C[n]1c2ncncc2nc1 VRZWCYZJGUYTKU-UHFFFAOYSA-N 0.000 description 1
- WESDBLALURHRDL-UHFFFAOYSA-N Cc1c2nccnc2ncn1 Chemical compound Cc1c2nccnc2ncn1 WESDBLALURHRDL-UHFFFAOYSA-N 0.000 description 1
- KDYVCOSVYOSHOL-UHFFFAOYSA-N Cc1cc(nccc2)c2cc1 Chemical compound Cc1cc(nccc2)c2cc1 KDYVCOSVYOSHOL-UHFFFAOYSA-N 0.000 description 1
- JRLTTZUODKEYDH-UHFFFAOYSA-N Cc1cccc2cccnc12 Chemical compound Cc1cccc2cccnc12 JRLTTZUODKEYDH-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32970501P | 2001-10-16 | 2001-10-16 | |
| PCT/US2002/033246 WO2003032921A2 (en) | 2001-10-16 | 2002-10-16 | Treatment of neurodegenerative diseases and cancer of the brain |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005506348A JP2005506348A (ja) | 2005-03-03 |
| JP2005506348A5 true JP2005506348A5 (enExample) | 2006-01-05 |
| JP4638148B2 JP4638148B2 (ja) | 2011-02-23 |
Family
ID=23286625
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003535727A Expired - Fee Related JP4638148B2 (ja) | 2001-10-16 | 2002-10-16 | 神経変性疾患および脳の癌の処置 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US20040087657A1 (enExample) |
| EP (2) | EP1443928B1 (enExample) |
| JP (1) | JP4638148B2 (enExample) |
| AT (1) | ATE517624T1 (enExample) |
| AU (2) | AU2002340253C1 (enExample) |
| CA (1) | CA2463552C (enExample) |
| WO (1) | WO2003032921A2 (enExample) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6511990B1 (en) * | 1999-09-08 | 2003-01-28 | Sloan-Kettering Institute For Cancer Research | Class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof |
| JP4638148B2 (ja) * | 2001-10-16 | 2011-02-23 | スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ | 神経変性疾患および脳の癌の処置 |
| US20040132825A1 (en) * | 2002-03-04 | 2004-07-08 | Bacopoulos Nicholas G. | Methods of treating cancer with HDAC inhibitors |
| EP2322160A1 (en) * | 2002-03-04 | 2011-05-18 | Merck HDAC Research, LLC | Methods of inducing terminal differentiation |
| US20040077591A1 (en) * | 2002-03-28 | 2004-04-22 | The Brigham And Women's Hospital, Inc. | Histone deacetylase inhibitors for the treatment of multiple sclerosis, amyotrophic lateral sclerosis and Alzheimer's Disease |
| MXPA04010199A (es) * | 2002-04-15 | 2005-07-05 | Sloan Kettering Inst Cancer | Terapia en combinacion para el tratamiento de cancer. |
| US7154002B1 (en) | 2002-10-08 | 2006-12-26 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| US7250514B1 (en) | 2002-10-21 | 2007-07-31 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| JP2006512318A (ja) * | 2002-11-12 | 2006-04-13 | アルコン，インコーポレイテッド | 眼の血管新生もしくは水腫状の疾患および障害を処置するためのヒストンデアセチラーゼインヒビター |
| GB0226855D0 (en) * | 2002-11-18 | 2002-12-24 | Queen Mary & Westfield College | Histone deacetylase inhibitors |
| CA2518318A1 (en) | 2003-03-17 | 2004-09-30 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| WO2004089293A2 (en) * | 2003-04-01 | 2004-10-21 | Memorial Sloan-Kettering Cancer Center | Hydroxamic acid compounds and methods of use thereof |
| US20050075282A1 (en) * | 2003-10-01 | 2005-04-07 | Douglas Coulter | Materials and methods for inhibiting the development of epilepsy |
| WO2005034880A2 (en) * | 2003-10-09 | 2005-04-21 | Aton Pharma, Inc. | Thiophene and benzothiophene hydroxamic acid derivatives |
| US20090023718A1 (en) * | 2003-11-26 | 2009-01-22 | Aton Pharma, Inc. | Diamine and Iminodiacetic Acid Hydroxamic Acid Derivatives |
| US20080004290A1 (en) * | 2003-11-28 | 2008-01-03 | The University Of Queensland | Anti-Cancer Agents |
| WO2005066151A2 (en) * | 2003-12-19 | 2005-07-21 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| US20050159470A1 (en) * | 2003-12-19 | 2005-07-21 | Syrrx, Inc. | Histone deacetylase inhibitors |
| US20050197336A1 (en) * | 2004-03-08 | 2005-09-08 | Miikana Therapeutics Corporation | Inhibitors of histone deacetylase |
| US7345043B2 (en) * | 2004-04-01 | 2008-03-18 | Miikana Therapeutics | Inhibitors of histone deacetylase |
| JP4993374B2 (ja) * | 2004-04-05 | 2012-08-08 | メルク エイチディーエーシー リサーチ エルエルシー | ヒストン脱アセチル化酵素インヒビタープロドラッグ |
| CN101035542A (zh) * | 2004-08-25 | 2007-09-12 | 默克公司 | 组蛋白脱乙酰基酶抑制剂 |
| US7901675B2 (en) | 2004-10-13 | 2011-03-08 | U.S. Department Of Veterans Affairs | Method of using coenzyme Q10 to treat Huntington's disease |
| EP1824831A2 (en) | 2004-12-16 | 2007-08-29 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| CA2596015A1 (en) | 2005-02-14 | 2006-08-24 | Sampath K. Anandan | Fused heterocyclic compounds useful as inhibitors of histone deacetylase |
| AU2006228957A1 (en) * | 2005-04-01 | 2006-10-05 | Methylgene Inc. | Inhibitors of histone deacetylase |
| WO2006117165A2 (en) * | 2005-05-02 | 2006-11-09 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Means and methods for the treatment of head injuries and stroke |
| JP2008540574A (ja) | 2005-05-11 | 2008-11-20 | タケダ サン ディエゴ インコーポレイテッド | ヒストンデアセチラーゼ阻害剤 |
| TWI415603B (zh) * | 2005-05-20 | 2013-11-21 | Merck Sharp & Dohme | １，８－辛二醯基苯胺羥胺酸（ｓｕｂｅｒｏｙｌａｎｉｌｉｄｅ ｈｙｄｒｏｘａｍｉｃ ａｃｉｄ）之調配物及其製配方法 |
| US8158825B2 (en) | 2005-06-24 | 2012-04-17 | Merck Sharp & Dohme Corp. | Modified malonate derivatives |
| CN101263121A (zh) | 2005-07-14 | 2008-09-10 | 塔克达圣地亚哥公司 | 组蛋白脱乙酰基酶抑制剂 |
| US20090105329A1 (en) * | 2005-11-04 | 2009-04-23 | Judy Chiao | Methods of Treating Cancers with SAHA, Carboplatin, and Paclitaxel and Other Combination Therapies |
| EP1976835A2 (en) * | 2006-01-13 | 2008-10-08 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| US20090018142A9 (en) * | 2006-05-02 | 2009-01-15 | Zhengping Zhuang | Use of phosphatases to treat tumors overexpressing N-CoR |
| WO2007130419A2 (en) * | 2006-05-04 | 2007-11-15 | Merck & Co., Inc. | Histone deacetylase inhibitors for the treatment of neurodegeneration |
| JPWO2008004610A1 (ja) * | 2006-07-05 | 2009-12-03 | 国立大学法人 東京大学 | ナンセンス変異型遺伝性疾患の治療方法 |
| CA2667826C (en) | 2006-10-28 | 2013-10-08 | Methylgene Inc. | Inhibitors of histone deacetylase |
| US8088951B2 (en) | 2006-11-30 | 2012-01-03 | Massachusetts Institute Of Technology | Epigenetic mechanisms re-establish access to long-term memory after neuronal loss |
| CN101662939B (zh) | 2007-02-06 | 2015-11-25 | 利克斯特生物技术公司 | 氧杂双环庚烷和氧杂双环庚烯，它们的制备及用途 |
| CA2679629A1 (en) * | 2007-02-27 | 2008-09-04 | Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services | Use of histone deacetylase inhibitors for the treatment of central nervous system metastases |
| US20100278730A1 (en) * | 2007-04-12 | 2010-11-04 | Sabrina Ronen | Non-Invasive Molecular Imaging of Cellular Histone Deacetylase Substrate Using Magnetic Resonance Spectroscopy (MRS) or Positron Emission Tomography (PET) |
| AU2008269154B2 (en) | 2007-06-27 | 2014-06-12 | Merck Sharp & Dohme Llc | 4-carboxybenzylamino derivatives as histone deacetylase inhibitors |
| WO2009011795A2 (en) * | 2007-07-13 | 2009-01-22 | Massachusetts Institute Of Technology | Methods for treating stress induced emotional disorders |
| AU2008284364A1 (en) * | 2007-08-03 | 2009-02-12 | Lixte Biotechnology, Inc. | Use of phosphatases to treat neuroblastomas and medulloblastomas |
| AU2008307541B2 (en) | 2007-10-01 | 2015-02-12 | Lixte Biotechnology, Inc. | HDAC inhibitors |
| US8263547B2 (en) | 2008-05-28 | 2012-09-11 | Massachusetts Institute Of Technology | DISC-1 pathway activators in the control of neurogenesis |
| CA2734991A1 (en) * | 2008-07-23 | 2010-01-28 | Massachusetts Institute Of Technology | Activation of histone deacetylase 1 (hdac1) protects against dna damage and increases neuronal survival |
| US8227473B2 (en) | 2008-08-01 | 2012-07-24 | Lixte Biotechnology, Inc. | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use |
| WO2010014141A1 (en) * | 2008-08-01 | 2010-02-04 | Lixte Biotechnology, Inc. | Methods for regulating cell mitosis by inhibiting serine/threonine phosphatase |
| EP2318005B1 (en) * | 2008-08-01 | 2017-11-01 | Lixte Biotechnology, Inc. | Neuroprotective agents for the prevention and treatment of neurodegenerative diseases |
| NZ599757A (en) | 2009-10-30 | 2014-08-29 | Massachusetts Inst Technology | The use of ci-994 and dinaline for the treatment of memory/cognition and anxiety disorders |
| CN102775368B (zh) * | 2011-05-10 | 2016-08-17 | 上海驺虞医药科技有限公司 | 一类噻唑类化合物及其制备方法和用途 |
| ES2719266T3 (es) | 2011-07-22 | 2019-07-09 | Massachusetts Inst Technology | Activadores de histona desacetilasas de clase I (HDACS), y usos de los mismos |
| WO2013066836A1 (en) * | 2011-10-31 | 2013-05-10 | Glaxosmithkline Llc | Compounds and methods |
| CA2909160C (en) | 2013-04-09 | 2021-05-25 | Lixte Biotechnology, Inc. | Formulations of oxabicycloheptanes and oxabicycloheptenes |
| JP7246309B2 (ja) | 2016-12-08 | 2023-03-27 | リクスト・バイオテクノロジー，インコーポレイテッド | 免疫応答を調節するためのオキサビシクロヘプタン |
| WO2019140417A1 (en) * | 2018-01-15 | 2019-07-18 | Daly Thomas P | Aminopyridine based buffers with wide buffering ranges antibiotics and myelin disease therapy |
| US11453661B2 (en) | 2019-09-27 | 2022-09-27 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| WO2023287984A1 (en) * | 2021-07-14 | 2023-01-19 | University Of Maryland, Baltimore | Suberoylanilide hydroxamic acid (saha) drugs, conjugates, and nanoparticles, and methods of use thereof |
| KR102859315B1 (ko) * | 2024-02-27 | 2025-09-12 | 주식회사 아이피에스바이오 | 히스톤 탈아세틸효소 저해제를 포함하는 다중 글루타민 질병의 예방 또는 치료용 약학적 조성물 |
| KR20250131624A (ko) * | 2024-02-27 | 2025-09-03 | 주식회사 아이피에스바이오 | 히스톤 탈아세틸효소 저해제를 포함하는 인지기능 장애의 예방 또는 치료용 약학적 조성물 |
Family Cites Families (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61176523A (ja) * | 1985-01-30 | 1986-08-08 | Teruhiko Beppu | 制癌剤 |
| US5330744A (en) * | 1988-11-14 | 1994-07-19 | Sloan-Kettering Institute For Cancer Research | Method for increasing sensitivity to chemically induced terminal differentiation |
| WO1990009092A2 (en) | 1988-11-14 | 1990-08-23 | The Trustees Of Columbia University In The City Of New York | Novel potent inducers of terminal differentiation and method of use thereof |
| US5055608A (en) * | 1988-11-14 | 1991-10-08 | Sloan-Kettering Institute For Cancer Research | Novel potent inducers of thermal differentiation and method of use thereof |
| US5608108A (en) * | 1988-11-14 | 1997-03-04 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and method of use thereof |
| US5175191A (en) | 1988-11-14 | 1992-12-29 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and methods of use thereof |
| USRE38506E1 (en) * | 1991-10-04 | 2004-04-20 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and methods of use thereof |
| US5700811A (en) | 1991-10-04 | 1997-12-23 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and method of use thereof |
| US5369108A (en) * | 1991-10-04 | 1994-11-29 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and methods of use thereof |
| US5635532A (en) * | 1991-10-21 | 1997-06-03 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Compositions and methods for therapy and prevention of pathologies including cancer, AIDS and anemia |
| HU9203780D0 (en) | 1991-12-12 | 1993-03-29 | Sandoz Ag | Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them |
| JPH07196686A (ja) | 1994-01-06 | 1995-08-01 | Takeda Chem Ind Ltd | 化合物ｔａｎ−１７４６類、その製造法および用途 |
| EP0855024A4 (en) | 1995-09-20 | 2001-08-22 | Merck & Co Inc | HISTONE DEACETYLASE AS THE ATTACK POINT FOR ANTIPROTOZOIC ACTIVE SUBSTANCES |
| GB2309696B (en) | 1996-01-31 | 2000-02-23 | Merck & Co Inc | Antiprotozoal cyclic tetrapeptides |
| US6777217B1 (en) | 1996-03-26 | 2004-08-17 | President And Fellows Of Harvard College | Histone deacetylases, and uses related thereto |
| US6124495A (en) | 1997-03-11 | 2000-09-26 | Beacon Laboratories, Inc. | Unsaturated oxyalkylene esters and uses thereof |
| US6043389A (en) * | 1997-03-11 | 2000-03-28 | Mor Research Applications, Ltd. | Hydroxy and ether-containing oxyalkylene esters and uses thereof |
| US6030961A (en) | 1997-03-11 | 2000-02-29 | Bar-Ilan Research & Development Co., Ltd. | Oxyalkylene phosphate compounds and uses thereof |
| US6231880B1 (en) * | 1997-05-30 | 2001-05-15 | Susan P. Perrine | Compositions and administration of compositions for the treatment of blood disorders |
| AUPO721997A0 (en) | 1997-06-06 | 1997-07-03 | Queensland Institute Of Medical Research, The | Anticancer compounds |
| US6262116B1 (en) * | 1998-01-23 | 2001-07-17 | Sloan-Kettering Institute For Cancer Research | Transcription therapy for cancers |
| EP0931792B1 (en) | 1998-01-27 | 2004-01-07 | Nisshin Seifun Group Inc. | Depsipeptides containing non-natural amino acids |
| JP4405602B2 (ja) * | 1998-04-16 | 2010-01-27 | バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト | ヒストン脱アセチル化酵素阻害剤 |
| JPH11335375A (ja) * | 1998-05-20 | 1999-12-07 | Mitsui Chem Inc | ヒストン脱アセチル化酵素阻害作用を有するベンズアミド誘導体 |
| AUPP505798A0 (en) * | 1998-08-04 | 1998-08-27 | Fujisawa Pharmaceutical Co., Ltd. | Novel compound fr225497 substance |
| JP2002527449A (ja) * | 1998-10-13 | 2002-08-27 | 藤沢薬品工業株式会社 | 環状テトラペプチド化合物およびその用途 |
| ATE275956T1 (de) | 1998-10-19 | 2004-10-15 | Methylgene Inc | Veränderung der dns methyltransferase durch kombinationstherapie |
| JP2000256194A (ja) * | 1999-01-06 | 2000-09-19 | Mitsui Chemicals Inc | 核内レセプタ作動薬およびその効果増強剤 |
| JP4269041B2 (ja) | 1999-03-02 | 2009-05-27 | 国立大学法人九州工業大学 | 新規な環状テトラペプチド誘導体とその医薬用途 |
| JP2003500052A (ja) | 1999-05-03 | 2003-01-07 | メチルジーン インコーポレイテッド | ヒストン脱アセチル酵素の抑制 |
| WO2001014581A2 (en) | 1999-08-20 | 2001-03-01 | Board Of Regents, The University Of Texas System | Hdac4 and hdac5 in the regulation of cardiac gene expression |
| JP2001081031A (ja) | 1999-08-30 | 2001-03-27 | Schering Ag | 溶解性および経口吸収性を改善したベンズアミド誘導体含有製剤 |
| DE60034688T2 (de) | 1999-09-08 | 2008-01-17 | Sloan-Kettering Institute For Cancer Research | Kristallstruktur einer deacetylase und deren inhibitoren |
| US6511990B1 (en) * | 1999-09-08 | 2003-01-28 | Sloan-Kettering Institute For Cancer Research | Class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof |
| US6575845B2 (en) * | 1999-11-01 | 2003-06-10 | Callaway Golf Company | Multiple material golf club head |
| US6541661B1 (en) | 1999-11-23 | 2003-04-01 | Methylgene, Inc. | Inhibitors of histone deacetylase |
| WO2001042437A2 (en) | 1999-12-08 | 2001-06-14 | Axys Pharmaceuticals, Inc. | Histone deacetylase-8 proteins, nucleic acids, and methods of use |
| WO2003006652A2 (en) * | 2000-03-24 | 2003-01-23 | Methylgene, Inc. | Inhibition of specific histone deacetylase isoforms |
| ATE489360T1 (de) | 2000-03-24 | 2010-12-15 | Methylgene Inc | Inhibitoren der histon-deacetylase |
| JP2001348340A (ja) | 2000-06-07 | 2001-12-18 | Yamanouchi Pharmaceut Co Ltd | ヒストン脱アセチル化酵素阻害剤 |
| JP2001354694A (ja) * | 2000-06-13 | 2001-12-25 | Yamanouchi Pharmaceut Co Ltd | ジチオール誘導体 |
| ES2277923T3 (es) * | 2000-07-06 | 2007-08-01 | Sumitomo Chemical Company, Limited | Insecticidas. |
| EP1170008A1 (en) | 2000-07-07 | 2002-01-09 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Valproic acid and derivatives thereof as histone deacetylase inhibitors |
| AU2001285042A1 (en) | 2000-08-18 | 2002-03-04 | The Governement Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Methods of treating cutaneous and peripheral t-cell lymphoma by a histone deacetylase inhibitor |
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| US20050004007A1 (en) * | 2000-09-12 | 2005-01-06 | Steven Grant | Promotion of adoptosis in cancer cells by co-administration of cyclin dependent kinase inhibitiors and cellular differentiation agents |
| WO2002030879A2 (en) | 2000-09-29 | 2002-04-18 | Prolifix Limited | Carbamic acid compounds comprising a sulfonamide linkage as hdac inhibitors |
| EP2083005A1 (en) | 2000-09-29 | 2009-07-29 | TopoTarget UK Limited | Carbamic acid compounds comprising an amide linkage as HDAC inhibitors |
| GB0023983D0 (en) | 2000-09-29 | 2000-11-15 | Prolifix Ltd | Therapeutic compounds |
| US20020103192A1 (en) | 2000-10-26 | 2002-08-01 | Curtin Michael L. | Inhibitors of histone deacetylase |
| WO2002055017A2 (en) * | 2000-11-21 | 2002-07-18 | Wake Forest University | Method of treating autoimmune diseases |
| AR035659A1 (es) * | 2000-12-07 | 2004-06-23 | Hoffmann La Roche | Hidroxiamidas de acido (1-oxo-1,2,3,4-tetrahidro-naftalen-2-il)-alcanoico, proceso para la manufactura de estos compuestos, composiciones farmaceuticas que contienen dichos compuestos y los usos de los mismos |
| WO2002050285A2 (en) | 2000-12-20 | 2002-06-27 | Novartis Ag | Histone deacetylase-related gene and protein |
| AR035513A1 (es) | 2000-12-23 | 2004-06-02 | Hoffmann La Roche | Derivados de tetrahidropiridina, proceso para prepararlos, composiciones farmaceuticas que los contienen, y uso de dichos compuestos en la preparacion de medicamentos |
| US6495719B2 (en) * | 2001-03-27 | 2002-12-17 | Circagen Pharmaceutical | Histone deacetylase inhibitors |
| US6905669B2 (en) * | 2001-04-24 | 2005-06-14 | Supergen, Inc. | Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase |
| WO2002090534A1 (en) | 2001-05-02 | 2002-11-14 | The Regents Of The University Of California | Method for treating neurodegenerative, psychiatric and other disorders with deacetylase inhibitors |
| US20040142859A1 (en) * | 2002-05-02 | 2004-07-22 | Steffan Joan S. | Method for treating neurodegenerative, psychiatric, and other disorders with deacetylase inhibitors |
| AU2002318364A1 (en) * | 2001-06-14 | 2003-01-02 | Bristol-Myers Squibb Company | Novel human histone deacetylases |
| JP4638148B2 (ja) * | 2001-10-16 | 2011-02-23 | スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ | 神経変性疾患および脳の癌の処置 |
| US20040132643A1 (en) * | 2002-01-09 | 2004-07-08 | Fojo Antonio Tito | Histone deacelylase inhibitors in diagnosis and treatment of thyroid neoplasms |
| EP1482962A4 (en) * | 2002-02-15 | 2009-12-23 | Sloan Kettering Inst Cancer | METHOD OF TREATING THIOREDOXIN-MEDIATED DISEASES (TRX) |
| EP2322160A1 (en) * | 2002-03-04 | 2011-05-18 | Merck HDAC Research, LLC | Methods of inducing terminal differentiation |
| US20040132825A1 (en) * | 2002-03-04 | 2004-07-08 | Bacopoulos Nicholas G. | Methods of treating cancer with HDAC inhibitors |
| US7456219B2 (en) * | 2002-03-04 | 2008-11-25 | Merck Hdac Research, Llc | Polymorphs of suberoylanilide hydroxamic acid |
| US20060276547A1 (en) * | 2002-03-04 | 2006-12-07 | Bacopoulos Nicholas G | Methods of treating cancer with HDAC inhibitors |
| US7148257B2 (en) * | 2002-03-04 | 2006-12-12 | Merck Hdac Research, Llc | Methods of treating mesothelioma with suberoylanilide hydroxamic acid |
| US20070060614A1 (en) * | 2002-03-04 | 2007-03-15 | Bacopoulos Nicholas G | Methods of treating cancer with hdac inhibitors |
| US20040077591A1 (en) * | 2002-03-28 | 2004-04-22 | The Brigham And Women's Hospital, Inc. | Histone deacetylase inhibitors for the treatment of multiple sclerosis, amyotrophic lateral sclerosis and Alzheimer's Disease |
| MXPA04010199A (es) * | 2002-04-15 | 2005-07-05 | Sloan Kettering Inst Cancer | Terapia en combinacion para el tratamiento de cancer. |
| JP2006508986A (ja) * | 2002-11-20 | 2006-03-16 | エルラント ゲネ セラペウチクス エルエルシー | ヒストンデアセチラーゼ阻害剤による肺細胞の治療方法 |
| WO2004089293A2 (en) * | 2003-04-01 | 2004-10-21 | Memorial Sloan-Kettering Cancer Center | Hydroxamic acid compounds and methods of use thereof |
| CN1964714B (zh) * | 2003-08-29 | 2011-09-28 | Hdac默克研究有限责任公司 | 辛二酰苯胺异羟肟酸和吉西他滨在制备用于治疗癌症的药物中的用途 |
| WO2007136615A2 (en) * | 2006-05-16 | 2007-11-29 | Merck & Co., Inc. | Combination cancer therapy |
-
2002
- 2002-10-16 JP JP2003535727A patent/JP4638148B2/ja not_active Expired - Fee Related
- 2002-10-16 EP EP02778601A patent/EP1443928B1/en not_active Expired - Lifetime
- 2002-10-16 AU AU2002340253A patent/AU2002340253C1/en not_active Ceased
- 2002-10-16 US US10/273,401 patent/US20040087657A1/en not_active Abandoned
- 2002-10-16 CA CA2463552A patent/CA2463552C/en not_active Expired - Fee Related
- 2002-10-16 AT AT02778601T patent/ATE517624T1/de not_active IP Right Cessation
- 2002-10-16 WO PCT/US2002/033246 patent/WO2003032921A2/en not_active Ceased
- 2002-10-16 EP EP10183856A patent/EP2269609A3/en not_active Withdrawn
-
2005
- 2005-11-18 US US11/282,420 patent/US7879865B2/en not_active Expired - Fee Related
-
2006
- 2006-01-25 AU AU2006200326A patent/AU2006200326B2/en not_active Ceased
-
2011
- 2011-01-31 US US13/017,447 patent/US20110124731A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005506348A5 (enExample) | ||
| CA2463552A1 (en) | Treatment of neurodegenerative diseases and cancer of the brain | |
| JP2005526857A5 (enExample) | ||
| CA2426601C (en) | Cyanoguanidine prodrugs | |
| JP2003528852A5 (enExample) | ||
| JP2003519676A5 (enExample) | ||
| RU2007105970A (ru) | Пиперидиновые производные в качестве лигандов гистаминового из рецептора | |
| CN1311676A (zh) | 抑制整联蛋白与其受体结合的化合物 | |
| WO2006038594A1 (ja) | Ｎ型カルシウムチャネル阻害薬 | |
| JP2835731B2 (ja) | ピペリジニル化合物類 | |
| JP2002527414A5 (enExample) | ||
| JP2015522551A5 (enExample) | ||
| JP2008518969A5 (enExample) | ||
| KR960704876A (ko) | 혈소판 응집 저해 작용을 갖는 신규 화합물 (Novel Compound Having Platelet Aggregation Inhibitor Effect) | |
| JPWO2023195529A5 (enExample) | ||
| RU2007105968A (ru) | Новые пиперидиновые производные для лечения депрессии | |
| CA2526991A1 (en) | Piperidinium and pyrrolidinium derivatives as ligands for the muscarinic m3 receptor | |
| JPH11501288A (ja) | 金属タンパク質分解酵素阻害剤 | |
| JP7416757B2 (ja) | 置換テトラヒドロシクロペンタ［ｃ］ピロール、置換ジヒドロピロリジン、その類似体、およびそれらを使用する方法 | |
| RU2004117595A (ru) | Производные пиридина в качестве лигандов рецептора nmda | |
| JP2005526138A5 (enExample) | ||
| CA3108046A1 (en) | Benzene derivative | |
| KR101179840B1 (ko) | 치환 또는 무치환 아미노기를 도입한 4-피리딜알킬티오기를갖는 신규 고리형 화합물 | |
| RU2019111188A (ru) | Кетоновые ингибиторы лизин-специфичного гингипаина | |
| WO2000015604A1 (fr) | Derives de diesters maloniques et leur procede d'obtention |